Health
Blood test could predict when Alzheimer’s symptoms will start years in advance
NEWYou can now listen to Fox News articles!
A simple blood test could predict not only a person’s risk of developing Alzheimer’s disease, but also the year symptoms will begin.
Researchers at the Washington University School of Medicine in St. Louis set out to determine if levels of a specific protein in the blood could be used as a “biological clock” to predict when signs of the disease will emerge.
The specific protein, known as p-tau217, forms “tangles” in the brain that disrupt communication between nerve cells. In a healthy brain, tau helps to stabilize the structure of nerve cells.
HIDDEN BRAIN CONDITION MAY QUADRUPLE DEMENTIA RISK IN OLDER ADULTS, STUDY SUGGESTS
In some cases, brain scans can be used to detect these tangles when diagnosing Alzheimer’s. Preliminary studies have suggested that the same method could be used to determine a progression timeline.
As these imaging tests are often complex and expensive, the research team wanted to explore whether a blood test could monitor the same proteins and produce similar results.
By comparing blood samples with participants’ cognitive performance over several years, the team found that p-tau217 levels rise in a “remarkably consistent” pattern long before memory loss begins. (iStock)
The study, published in the journal Nature Medicine, analyzed data from more than 600 older adults enrolled in two long-term Alzheimer’s research projects.
ALZHEIMER’S RISK TIED TO HOW THE BODY HANDLES SUGAR AFTER EATING, STUDY FINDS
By comparing blood samples with participants’ cognitive performance over several years, the team found that p-tau217 levels rise in a “remarkably consistent” pattern long before memory loss begins, according to a press release.
The team then created a model that uses a patient’s age and protein levels to estimate when symptoms will appear, with a margin of error of three to four years.
The team created a model that uses a patient’s age and protein levels to estimate when symptoms will appear, with a margin of error of three to four years. (iStock)
“We show that a single blood test measuring p-tau217 can provide a rough estimate of when an individual is likely to develop symptoms of Alzheimer’s disease,” lead author Kellen K. Petersen, PhD, instructor of neurology at Washington University in St. Louis, told Fox News Digital.
The researchers found that older adults developed symptoms much more rapidly after p-tau217 became abnormal, he noted.
LOWER DEMENTIA RISK LINKED TO ROUTINE VACCINATION IN MAJOR NEW ANALYSIS
“For example, people who first had abnormal p-tau217 levels around age 60 didn’t develop Alzheimer’s symptoms for about 20 years, whereas those who first had abnormal p-tau217 levels around age 80 developed symptoms after only about 10 years,” Petersen said.
This suggests that age and disease-related changes in the brain can influence how quickly Alzheimer’s symptoms become apparent, the researcher concluded.
“At this point, we do not recommend that any cognitively unimpaired individuals have any Alzheimer’s disease biomarker test.”
“This could transform how researchers design clinical trials and, eventually, how clinicians identify people at highest risk for cognitive decline associated with Alzheimer’s years before decline begins,” Chicago-based Rebecca M. Edelmayer, PhD, vice president of scientific engagement at the Alzheimer’s Association, told Fox News Digital.
“A blood test is generally much less expensive and easier to administer than a brain scan or spinal‑fluid test. In the future, it could help doctors and researchers identify people who may benefit from early treatments,” added Edelmayer, who was not involved in the study.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The study did have some limitations and caveats.
“We were only able to make predictions for individuals whose p-tau217 levels fell within a certain range, although it was a fairly wide range,” Petersen shared. “The models were developed in relatively healthy and well-educated research cohorts that were not diverse, so the results may not apply well to the broader population.”
The research suggests that age and disease-related changes in the brain can influence how quickly Alzheimer’s symptoms become apparent. (iStock)
While the researchers referenced in-home blood tests in this study, they cautioned against people seeking out and taking these tests themselves.
CLICK HERE FOR MORE HEALTH STORIES
“At this point, we do not recommend that any cognitively unimpaired individuals have any Alzheimer’s disease biomarker test,” Dr. Suzanne Schindler, a neurologist at Washington University who was a co-author of the study, said in the press release.
Peterson acknowledged that these results are still experimental and ripe for improvement.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“The current estimate is not yet accurate enough for clinical use or personal medical decision-making, but we expect that it will be possible to create more accurate models,” he told Fox News Digital.
Looking ahead, the team hopes to refine the test by researching other Alzheimer’s-linked proteins to narrow the margin of error, Schindler said. More diverse participants are also needed to confirm the results.
Two large clinical trials are in progress to determine whether people with high levels of the protein can benefit from treatment. (iStock)
Two large clinical trials are now in progress, aiming to determine whether people with high levels of this protein can benefit from treatment with one of two Alzheimer’s drugs before symptoms appear.
Lecanemab and donanemab are the only approved drugs designed to reduce levels of plaques in the brain associated with Alzheimer’s disease. Researchers hope that treating people earlier may boost the drugs’ effectiveness.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“There are many other blood and imaging biomarkers, as well as cognitive tests, that we can combine with plasma p-tau217 to improve the accuracy of predicting symptom onset,” Petersen said. “We hope this work will lead to even better models that will be useful to individuals.”
Health
With a Friend in Trump, the Tobacco Industry Secures a Lucrative Win
Over lunch at his golf club in Jupiter, Fla., on the first Saturday of May, President Trump got an earful from a group of tobacco executives and lobbyists unhappy with the way the Food and Drug Administration was regulating their industry.
Eventually Mr. Trump had heard enough. He interrupted the conversation to call Dr. Marty Makary, the F.D.A. commissioner.
No answer.
Furious, the president then dialed Dr. Makary’s boss, Health Secretary Robert F. Kennedy Jr., and another top health official, Dr. Mehmet Oz, the head of the Centers for Medicare and Medicaid Services. He complained to them about the F.D.A.’s regulation of e-cigarettes, according to three people briefed on the meeting who were not authorized to discuss it.
The message was received. Less than one week later, the executives got what they wanted.
On Friday, the F.D.A. issued new guidance that could pave the way for major tobacco companies to begin selling flavored vapes and to snare a chunk of the $6 billion e-cigarette market away from illegal Chinese competitors. The new policy bypassed the F.D.A.’s regular rule-making process.
In the intervening week, Dr. Makary continued to argue against approving flavored vapes as support from Mr. Kennedy and others collapsed around him. Health and Human Services Department staff began to draft the new plan, according to two people familiar with the events.
On Tuesday, Dr. Makary resigned, telling associates he could not in good conscience remain the head of an agency that backed such a policy.
Though there is no definitive evidence linking the new guidance to donations or lobbying, the episode represented a clear pivot in the federal government’s longtime approach to the tobacco industry.
Since the 1990s, when states extracted vast payments and other concessions from the major cigarette companies in a nationwide legal settlement, Big Tobacco has been in retreat. Cigarette sales have plummeted, and regulations have mounted as consumers and administrations from both parties embraced public health consensus about the dangers of smoking and nicotine addiction.
Mr. Trump’s first administration initially continued the trend, proposing further restrictions on cigarettes and moving to outlaw flavored vapes over concerns that their rising popularity threatened the health of a generation of adolescents.
But since then, Mr. Trump has enthusiastically welcomed the financial support of the tobacco industry and has courted e-cigarette users as a political constituency.
The new vaping guidance highlights Mr. Trump’s willingness to use his executive authority to prioritize the causes of major corporate donors over public health concerns, taxpayer interests and the judgment of experts, sometimes including those in his own administration.
The president has developed a close relationship with tobacco companies including Altria and Reynolds American, which have donated millions of dollars to his political groups and projects, including his proposed White House ballroom. Their executives attended the lunch at the president’s golf club.
The Department of Health and Human Services, which oversees the F.D.A., referred requests for comment to the White House.
Kush Desai, a White House spokesman, said in a statement that Mr. Trump has pushed to expand access to vapes to help Americans trying to quit smoking.
“The only guiding factor behind the Trump administration’s health policymaking is gold standard science,” Mr. Desai said.
Reynolds American and Altria did not respond to questions about their lobbying or the conversation at the lunch.
It was attended by Jeff Raborn, a top executive at Reynolds, and Phil Park and Todd Walker of Altria, according to the people familiar with the meeting. Also attending were Brian Ballard and Rich Haselwood, lobbyists for the firm Ballard Partners, which represents Reynolds and helped marshal a sophisticated and expensive influence campaign that culminated in the new vaping guidance. Mr. Ballard is a top fund-raiser for Mr. Trump. Mr. Haselwood had been an in-house lobbyist at Reynolds before joining Ballard Partners this year.
A spokesman for Ballard Partners declined to comment.
While public health experts consider e-cigarettes a less harmful alternative to tobacco-burning cigarettes, the new guidance circumvents a scientific review process the F.D.A. had previously defended up to the Supreme Court. The disregarded procedures were meant to ensure approval of only those products shown in studies to help cigarette smokers transition to vapes without attracting a new generation of nicotine users.
The guidance also could allow higher nicotine levels in nicotine pouches. It includes a pledge to prioritize efforts to stop the import of illegal foreign vapes, an idea that has bipartisan support in Congress.
Taken together, the policy changes could help companies like Altria and Reynolds gain market share considered central to the survival of the industry.
The market for vapes and nicotine pouches, like Zyn, is about 30 million people in the United States, on par with the number of cigarette smokers. While the nicotine pouch market is rapidly growing, cigarettes still account for about $50.8 billion, or nearly 70 percent of the annual tobacco sales in the United States, according to a Goldman Sachs research report. Vape sales have lagged amid competition from illicit products.
In recent years, the F.D.A. has moved glacially to approve e-cigarettes, authorizing only those in tobacco or menthol flavors, including some sold by Reynolds and Altria. Unapproved Chinese vapes have poured into the United States, feeding a thriving illicit market with flavors like peach slush and watermelon ice. Last year, industry executives have said, illicit fruit-flavored vapes made up 60 percent of the e-cigarette market.
When Mr. Trump mounted his bid to return to the White House, some in the tobacco industry went all in, hoping he would loosen regulations on vapes and abandon plans by the Biden administration to ban menthol cigarettes and crack down on other cigarette sales.
Mr. Trump in some ways makes for an unlikely savior for the tobacco industry. He has never smoked, but he pledged during his 2024 campaign to “save vaping again.”
Through a subsidiary, Reynolds, which is the biggest seller of menthol cigarettes, donated $10 million to a super PAC backing Mr. Trump’s campaign, according to campaign finance filings. There is no public record of the subsidiary donating to groups supporting Mr. Biden or the campaign of former Vice President Kamala Harris.
Mr. Ballard, whose firm has been paid more than $4.4 million by Reynolds since the beginning of 2017, arranged for Mr. Trump to have dinner during the campaign with Reynolds executives in New York, according to a person familiar with the interactions. The executives urged Mr. Trump to oppose the menthol cigarette ban and expressed concern about Chinese vapes.
Reynolds executives including Mr. Raborn and Mr. Haselwood were such a presence around the campaign that Mr. Trump took to calling them “my tobacco guys,” according to the person familiar with the interactions and a book coauthored by a New York Times reporter and published last year.
When Mr. Trump won, the rest of the industry jockeyed to show support.
Altria donated $1 million to his inaugural committee; the Vapor Technology Association donated $1.25 million; and a subsidiary of Philip Morris donated $500,000.
On Mr. Trump’s second full day in office, his administration withdrew the proposed ban on menthol cigarettes, an initiative the Biden administration had already mostly abandoned. Mr. Trump’s team also set aside a Biden-era proposal to sharply restrict nicotine in cigarettes, an effort meant to speed the transition away from a product known to be deadly.
In applauding the withdrawal of the menthol ban, Billy Gifford, the chief executive of Altria, told investors on an April 2025 earnings call that “we’re hopeful that that activity and momentum continues.”
The courtship intensified.
Reynolds pitched in another $3 million to a different Trump-backed super PAC, while Altria and Juul each donated $1 million.
And Reynolds and Altria each donated to the effort to raise private funds to build a new White House ballroom. Mr. Raborn of Reynolds and Mr. Walker of Altria were invited to a dinner at the White House in October for donors who gave $2.5 million or more, as was Mr. Ballard.
Tadeu Marroco, the chief executive of British American Tobacco, which owns Reynolds American, predicted to investors earlier this year that the Trump administration would clamp down on illegal vapes, saying “it’s very encouraging, the signs that the new administration is giving to address that.”
The companies’ lobbying strategy also has reached into the states, where they are pushing for so-called “registry laws” — of which there are now more than a dozen including in Florida, Virginia and Pennsylvania. Many of those laws restrict e-cigarette sales to only vapes on a list from the F.D.A.
The guidance released last week said it would create such a list.
Sheryl Gay Stolberg contributed reporting.
Health
First clade I mpox case confirmed in Connecticut after patient traveled to Western Europe
NEWYou can now listen to Fox News articles!
A case of clade I mpox — a more virulent version of the virus that causes monkeypox, according to the Centers of Disease Control and Prevention (CDC) — has been confirmed in the U.S., as global health officials also monitor newly reported hantavirus cases in Europe.
The Connecticut Department of Public Health (CDPH) said Wednesday that the state’s first identified case of clade I mpox was detected in a person who recently traveled to Western Europe, where officials continue to monitor infectious disease activity.
The World Health Organization (WHO) has also reported new hantavirus cases in Spain and France, drawing attention to the rare but potentially severe disease, which can cause serious respiratory complications in humans.
Hantavirus is typically spread through contact with infected rodents and can lead to severe respiratory illness, though cases remain rare, according to the WHO.
While health officials said the mpox case “does not pose a risk to the general public,” they still encourage those who may be at risk to receive the JYNNEOS vaccine.
NEW MPOX STRAIN CONFIRMED IN US STATE FOR FIRST TIME
A pharmacist wearing a latex glove holds a photo of the mpox virus, which can spread through close, intimate contact with an infected person. (iStock)
Mpox symptoms can include fever, swollen lymph nodes and a characteristic rash, according to CDC.
“Mpox hasn’t gone away, and we want people to be protected, especially as many in our community prepare for travel, festivals, and gatherings this summer,” CDPH Commissioner Dr. Manisha Juthani said in the release.
“The vaccine is safe, effective and widely available. Completing the two-dose series is the best way to protect yourself and your partners.”
HANTAVIRUS DEATHS ON CRUISE SHIP HIGHLIGHT DANGERS OF RODENT-BORNE DISEASE
Clade I mpox, a newer strain of the virus, first appeared in California in November 2024. (iStock)
Clade I and clade II mpox are genetically distinct forms of the virus with key differences in severity and geographic origin, according to the CDC and the WHO.
Clade I, historically identified in Central Africa, has been linked to more severe illness and higher mortality rates, with cases often involving more widespread rashes and complications.
A traveler walks past a sign in a busy airport about mpox. (Yasuyoshi Chiba/AFP)
Clade II, which has circulated primarily in West Africa, is generally associated with milder disease and drove the global outbreak beginning in 2022, when most patients experienced less severe symptoms and lower hospitalization and death rates, according to the WHO.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The CDC and WHO say distinguishing between the two clades helps guide risk assessments, particularly as international travel increases.
Health
The everyday places Americans could be exposed to hantavirus — without knowing it
NEWYou can now listen to Fox News articles!
Amid the current hantavirus outbreak that started on the MV Hondius cruise ship as it sailed across the Atlantic, health experts are now examining whether Americans may be encountering the virus in everyday places without realizing it.
The rare Andes strain, which was linked to the MV Hondius outbreak, is the only known hantavirus that has the capability to spread from person to person, usually through prolonged close contact with an infected person.
Most cases of hantavirus in the U.S. occur in the desert Southwest and on the West Coast, according to Dr. Linda Yancey, an infectious disease specialist at Memorial Hermann in the Houston area.
ANDES VIRUS LINKED TO CRUISE SHIP DEATHS RAISES CONCERN OVER HUMAN-TO-HUMAN SPREAD
“In Texas, cases are mostly seen on the west side of the state,” she told Fox News Digital. “The strain of hantavirus native to east Texas and west Louisiana, the Bayou strain, is not as infectious in humans as the western strain, the Sin Nombre strain.”
Hantavirus is primarily spread through contact with infected rodents – primarily deer mice – and their urine, droppings or saliva. (iStock)
Hantavirus is mainly spread through contact with infected rodents – primarily deer mice – and their urine, droppings or saliva, according to the Centers for Disease Control and Prevention.
People can become infected after breathing in contaminated particles that are stirred into the air or touching contaminated surfaces and then touching their nose or mouth. More rarely, rodent bites can spread the virus.
HANTAVIRUS OUTBREAK TIMELINE HIGHLIGHTS KEY MOMENTS IN DEADLY CRUISE CRISIS
Exposure is most likely when cleaning enclosed or poorly ventilated areas where rodents may nest unnoticed for weeks or months, health officials say.
Risky locations can include garages, sheds, cabins, attics, barns and crawl spaces. Storage units, stables, kitchen cabinets and spaces behind appliances if rodents are present.
CLICK HERE FOR MORE HEALTH STORIES
Rodents can also nest in unused cars, RVs, campers and boats, which can be sources of exposure when reopened.
The National Park Service says that most human cases of hantavirus occur in the spring and are linked to buildings that become heavily infested with rodents over the winter.
The risk of inhalation is also higher when opening buildings that have gone unused for longer periods of time, sweeping dusty floors, or moving and unpacking boxes. (iStock)
“Most people are exposed when cleaning out sheds and garages where rodents have been living,” Yancey confirmed. “You can be exposed by just the dust and droppings left behind by rodents – you don’t even need to even see the rodent to be exposed.”
The risk of inhalation is also higher when opening buildings that have gone unused for longer periods of time, sweeping dusty floors or moving and unpacking boxes, experts cautioned.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Rodent exposure is not limited to buildings. Health officials say people can also encounter hantavirus risk while handling firewood, working in rodent-prone outdoor areas or disturbing rodent nests and burrows.
To prevent infection, if cleaning a structure that might have harbored rodents, Yancey recommends wearing a mask and using a diluted bleach solution to wet down any dust or loose debris.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“This will help kill the exposed virus and reduce the amount of infectious dust,” Yancey said.
The CDC advises against vacuuming or sweeping rodent urine, droppings or nesting materials, as this can aerosolize the virus and increase the risk of inhalation.
A Spanish passenger boards a government plane after disembarking from the hantavirus-stricken cruise ship MV Hondius at the airport in Tenerife, Canary Islands, on May 10, 2026. (Arturo Rodriguez/AP Photo)
Instead, health officials recommend wearing gloves, soaking rodent droppings with disinfectant, wiping them up with paper towels, properly disposing of waste and thoroughly cleaning surfaces, followed by careful handwashing.
Some signs of rodent activity can include droppings, shredded nesting materials, gnaw marks, strong musky odors and scratching sounds in the walls or ceilings, according to public health guidance.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Dr. Marc Siegel, Fox News senior medical analyst, emphasized that hantavirus is not something that most Americans encounter in daily life, and is more prominent in certain parts of Europe and Asia.
“It is very rare in the U.S. and is seen out west, but rarely,” he told Fox News Digital. “We need to avoid overpersonalizing the risk of a very rare virus.”
-
Nevada4 minutes agoArbor View beats rival Centennial for 5A boys volleyball state title
-
New Hampshire10 minutes agoEmily (Em) Madeline Peters
-
New Jersey16 minutes agoOlder NJ residents consider leaving as costs rise, survey shows
-
New Mexico22 minutes agoNew Mexico elementary school partners with NASA and earns elite STEM certification
-
North Carolina28 minutes agoPolice: North Carolina man charged after high-speed chase in Erie County, arrested in the Town of Perry
-
North Dakota34 minutes agoND Emergency Services receives wildfire prevention award
-
Ohio40 minutes agoA unique project asks Ohioans to map Revolutionary War graves
-
Oklahoma46 minutes agoOklahoma teacher turns PB&J’s into a lifeline for students